Search Within

Alison Moskowitz

Formats
  1. Meeting Abstract (181)
  2. Journal Article (123)
  3. Review (13)
  4. Research Letter (12)
  5. Editorial (5)
  6. Guidelines (3)
  7. Book Section (1)
  8. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (339)
  2. Department of Medicine (339)
  3. Hematologic Malignancies, Division of (339)
  4. Lymphoma (339)
  5. Population Sciences Research Program (220)
  6. Survivorship Research (141)

More Groups

People
  1. Steven Horwitz (220)
  2. Andrew Zelenetz (119)
  3. Paul Hamlin (107)
  4. Ariela Noy (106)
  5. David Straus (96)
  6. Matthew Matasar (95)

More People

Years
  1. 2025 (6)
  2. 2024 (22)
  3. 2023 (37)
  4. 2022 (20)
  5. 2021 (36)
  6. 2020 (30)

More Years

Publications
  1. Blood (136)
  2. Hematological Oncology (23)
  3. Journal of Clinical Oncology (21)
  4. Blood Advances (15)
  5. Journal of the American Academy of Dermatology (13)
  6. Leukemia and Lymphoma (13)

More Publications

Publishers
  1. American Society of Hematology (154)
  2. Wiley Blackwell (31)
  3. American Society of Clinical Oncology (24)
  4. Elsevier Inc. (21)
  5. Taylor & Francis Group (14)
  6. Mosby Elsevier (13)

More Publishers

Results (339)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes of adult T-cell leukemia/lymphoma with allogeneic stem cell transplantation: Single-institution experience
    Journal Article

    Epstein-Peterson, Z. D.; Ganesan, N.; Barker, J. N.; Drullinsky, P. R.; Ghione, P.; Jakubowski, A. A.; Kumar, A.; Moskowitz, A. J.; Noy, A.; Perales, M. A.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management
    Review

    Oh, Y.; Stoll, J. R.; Moskowitz, A.; Pulitzer, M.; Horwitz, S.; Myskowski, P.; Noor, S. J.
    Journal of the American Academy of Dermatology (2021)

    Fulltext@MSK | Save
  • CheckMate 436: Extended follow-up from the phase 2 study investigating nivolumab plus brentuximab vedotin (BV) for relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL)
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P.; Cunningham, D.; Kline, J.; Johnson, N.; Mehta-Shah, N.; Fanale, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Lymphomatoid papulosis: A retrospective review of clinical characteristics, symptomatology, treatments, and associated malignancies at a single institution
    Meeting Abstract

    Stoll, J.; Pulitzer, M.; Moskowitz, A.; Horwitz, S.; Myskowski, P. L.; Noor, S. J.
    Journal of the American Academy of Dermatology (2021)

    Fulltext@MSK | Save
  • Recommendations for testing and treating outpatient cancer patients in the era of COVID-19
    Guidelines

    Reidy-Lagunes, D.; Saltz, L.; Postow, M.; Scordo, M.; Moskowitz, A.; Tew, W.; Zamarin, D.; Redelman-Sidi, G.
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
    Journal Article

    Advani, R. H.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Christian, B. A.; Ansell, S. M.; Moskowitz, C. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Extended follow‐up from the phase 2 CheckMate 436 study
    Meeting Abstract

    Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save